# US 2025/0129357 A1 · Valencene synthase mutant and valencene high-yield strain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0129357 A1
- Document ID: US20250129357A1
- Status: Published application
- Kind: A1
- Application number: 18/728,070
- Filed: 2022-12-28
- Published: 2025-04-24
- Earliest claimed: 2022-01-11
- Assignees: Wuhan Hesheng Technology Co., Ltd.
- Applicants: Wuhan Hesheng Technology Co., Ltd.
- Inventors: Ziling YE
- Web page: https://patentgrep.com/patent/US20250129357A1

## CPC

- C12N 9/88: Lyases (4.)
- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12N 9/1029: {transferring groups other than amino-acyl groups (2.3.1)}
- C12N 9/1085: {transferring alkyl or aryl groups other than methyl groups (2.5)}
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- C12N 9/1229: {Phosphotransferases with a phosphate group as acceptor (2.7.4)}
- C12N 9/90: Isomerases (5.)
- C12N 15/81: for yeasts
- C12N 15/82: for plant cells {, e.g. plant artificial chromosomes (PACs)}
- C12P 5/00: Preparation of hydrocarbons {or halogenated hydrocarbons}
- C12P 5/002: {cyclic (compounds containing at least three condensed carbocyclic rings C12P15/00)}
- C12P 5/007: {containing one or more isoprene units, i.e. terpenes (carotenes C12P23/00)}
- C12P 7/26: Ketones
- C12R 2001/865: Saccharomyces cerevisiae
- C12Y 101/01088: Hydroxymethylglutaryl-CoA reductase (1.1.1.88)
- C12Y 203/01009: Acetyl-CoA C-acetyltransferase (2.3.1.9)
- C12Y 203/0301: Hydroxymethylglutaryl-CoA synthase (2.3.3.10)
- C12Y 205/01001: Dimethylallyltranstransferase (2.5.1.1)
- C12Y 207/01036: Mevalonate kinase (2.7.1.36)
- C12Y 207/04002: Phosphomevalonate kinase (2.7.4.2)
- C12Y 401/01033: Diphosphomevalonate decarboxylase (4.1.1.33), i.e. mevalonate-pyrophosphate decarboxylase
- C12Y 402/03073: Valencene synthase (4.2.3.73)
- C12Y 503/03002: Isopentenyl-diphosphate DELTA-isomerase (5.3.3.2)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12Y: ENZYMES

## Abstract

The present disclosure belongs to the field of synthetic biology and relates to a valencene synthase mutant and a valencene high-yield strain. An enzyme for synthesizing valencene is derived from Eryngium glaciale, and upon enzyme directed evolution of the enzyme, a valencene synthase mutant with improved enzyme performance is obtained, and the yield of a strain containing the mutant is 3.15 times the yield of a strain containing a wild-type synthase. The valencene synthase mutant of the present disclosure enhances the capability of synthesizing valencene by a strain, and a powerful foundation is laid for the industrial production thereof. A high-yield strain for synthesizing valencene is constructed by using the valencene synthetase mutant, and the yield of a fermentation tank reaches 12.4 g/L, which is the highest level reported to date.

## Claims

### Claim 1

A valencene synthase mutant, wherein the valencene synthase mutant has a substitution of an amino acid residue in at least one position selected from positions 533, 336, 196, 176, 306 and 325 compared to a wild-type valencene synthase, wherein the amino acid sequence of the wild-type valencene synthase is as shown in SEQ ID NO.1; and the positions are defined with reference to SEQ ID NO.1; the valencene synthase mutant has increased enzyme activity compared to the wild-type valencene synthase;
preferably, the valencene synthase mutant comprises at least one of I533V, R336K, H196R, D176E, R306K, and K325E mutations;
preferably, the valencene synthase mutant comprises I533V mutation, and optionally at least one of R336K, H196R, D176E, R306K, and K325E mutations;
preferably, the valencene synthase mutant comprises at least one of I533V and R336K mutations, and optionally at least one of H196R, D176E, R306K, and K325E mutations;
preferably, the amino acid sequence of the valencene synthase mutant is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence shown in SEQ ID NO: 1.

### Claim 2 (depends on 1)

A valencene synthase mutant according to claim 1, wherein the valencene synthase mutant comprises any one of the following mutation sites compared to the wild-type valencene synthase:
I533V and R336K;
I533V, R336K, H196R and D176E;
I533V, R336K and R306K;
I533V, R336K and K325E;
I533V, R336K, H196R, D176E, R306K and K325E;
preferably, the amino acid sequence of the valencene synthase mutant is least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequences shown in SEQ ID NOs. 92-96; preferably, the amino acid sequence of the valencene synthase mutant is as shown in SEQ ID NOs. 92-96.

### Claim 3 (depends on 1)

A gene encoding the valencene synthase mutant according to claim 1.

### Claim 4 (depends on 3)

A recombinant plasmid comprising the gene according to claim 3.

### Claim 5 (depends on 3)

A recombinant cell comprising the gene according to claim 3.

### Claim 6 (depends on 1)

Use of the valencene synthase mutant according to claim 1, the gene encoding the valencene synthase mutant according to claim 1, and the recombinant plasmid or the recombinant cell comprising the gene encoding the valencene synthase mutant according to claim 1 in the production of valencene and nootkatone.

### Claim 7 (depends on 3)

A valencene high-yield strain comprising the gene according to claim 3.

### Claim 8 (depends on 7)

The valencene high-yield strain according to claim 7, wherein the valencene high-yield strain comprises gene ERG20 encoding farnesyl pyrophosphate synthase and/or at least one of the genes in mevalonate (MVA) pathway, wherein the genes in mevalonate (MVA) pathway comprise: gene ERG10 encoding acetoacetyl coenzyme A thiolase, gene ERG13 encoding HMG-CoA synthase, gene tHMG1 encoding HMG-CoA reductase, gene ERG12 encoding mevalonate kinase, gene ERG8 encoding mevalonate-5-phosphate kinase, gene MVD1 encoding mevalonate pyrophosphate decarboxylase, and gene IDI1 encoding isoprene pyrophosphate isomerase;
preferably, the valencene high-yield strain comprises gene ERG20 encoding farnesyl pyrophosphate synthase; and further comprises a gene in mevalonate pathway, wherein the gene in mevalonate pathway comprises: gene ERG10 encoding acetoacetyl coenzyme A thiolase, gene ERG13 encoding HMG-CoA synthase, gene tHMG1 encoding HMG-CoA reductase, gene ERG12 encoding mevalonate kinase, gene ERG8 encoding mevalonate-5-phosphate kinase, gene MVD1 encoding mevalonate pyrophosphate decarboxylase, and gene IDI1 encoding isoprene pyrophosphate isomerase.

### Claim 9 (depends on 3)

The valencene high-yield strain comprising the gene according to claim 3 wherein the valencene high-yield strain comprises gene ERG20 encoding farnesyl pyrophosphate synthase; and further comprises a gene in mevalonate pathway, wherein the gene in mevalonate pathway comprises: gene ERG10 encoding acetoacetyl coenzyme A thiolase, gene ERG13 encoding HMG-CoA synthase, gene tHMG1 encoding HMG-CoA reductase, gene ERG12 encoding mevalonate kinase, gene ERG8 encoding mevalonate-5-phosphate kinase, gene MVD1 encoding mevalonate pyrophosphate decarboxylase, and gene IDI1 encoding isoprene pyrophosphate isomerase;
preferably, the copy numbers of the genes in MVA pathway and the farnesene pyrophosphate synthase gene are ERG10, ERG13, tHMG1, ERG12, ERG8, MVD1, IDI1, ERG20=2, 2, 3, 2, 2, 2, 2, 2; preferably, the copy number of the gene according to claim 3 is 2 or 3, preferably 2.

### Claim 10 (depends on 7)

The valencene high-yield strain according to claim 7, wherein the host of the high-yield valencene strain is Saccharomyces cerevisiae.

### Claim 11 (depends on 10)

The valencene high-yield strain according to claim 10, wherein the GAL80 gene in the valencene high-yield strain is knocked out.
